Stock Ratings / Health Care / WST / forecast

DXCM (76) RMD (86) MDLN (44) BDX (67) ⌘ Pro Terminal →

West Pharmaceutical Services Inc. (WST) 12-Month Stock Forecast & Price Target Cone

$412.62 -0.97% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $412.89

West Pharmaceutical Services Inc. (WST) earns a Roarable Rating of A- (Buy) with 81/100 RQD Confidence. High-quality cash engine (36% profit margin, 18% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 81/100 (A-) historically ranked in the Top 8% of excess returns over the next 90 days (+8.4% avg 90D alpha vs SPY • 71.6% hit rate) →

ROARABLE A- • BUY Cap $29.32B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on WST Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is WST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, West Pharmaceutical Services Inc. (NYSE: WST) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 81/100 at a spot price of $412.62 (-0.97% 1D, market cap $29.32B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, WST ranks #14 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does WST compare to DXCM and RMD in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), WST carries a Roarable A- (81/100 RQD), trailing P/E of 59.4x, gross margin of 35.9%, and ROIC of 17.9%. By comparison, DXCM (DexCom Inc.) holds a B+ grade (76/100 RQD, P/E 36.1x, ROIC 21.6%, cap $30.16B) and RMD (ResMed Inc.) posts a A grade (86/100 RQD, P/E 25.4x, ROIC 22.9%, cap $35.56B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for WST?

▼

Per WST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000105770), West Pharmaceutical Services Inc. generated $3.07B in revenue (+6.3% YoY), $493.7M in net income, and $468.9M in free cash flow against $4.27B in total assets and $202.8M in total debt. Key quantitative strengths: Strong cash generator (36% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 59x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $412.91 (+0.07%)🧬 Disciplined Float (+0.24% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 15.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 81/100 (A-) historically ranked in the Top 8% of excess returns over the next 90 days (+8.4% avg 90D alpha vs SPY • 71.6% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • A-

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk A-

Each axis scored 0–20

12M PRICE TARGET CONE+10.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WST)Realized 20D OHLCV Swing Band: ±5.3%

Deterministic 5-Pillar Attribution (81/100 Composite)

🔍 WHY WST SCORES 81/100 (A-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 15.3% FCF Margin ($468.9M FCF) & 35.9% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+18/20 pts (22% of score)

20D Institutional Volume Accumulation (±5.3% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution11/20 pts (-9 pt drag)

Disciplined Float (+0.24% YoY Shares) & executive Form 4 sales trim 9 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$371.82+4.6% Next Q

Q2 (-2Q)

Grade B+$388.78+2.4% Next Q

Q3 (-1Q)

Grade A-$398.29+3.6% Next Q

Current

Grade A-$412.62+8.4% Hist 90D α

Trajectory: B (73) → A- (81)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the WST Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 81/100 (A-) score, WST faces multiple-compression risk if 59.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 59x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+0.24% YoY Shares) — any gross margin slip below 33.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($370.14) or 200D SMA ($314.85) invalidates the momentum regime and cuts Target Base ($455.33) toward Bear Floor ($338.35).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WST• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “WST Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 81%NO 19%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your WST Position Size: $10,000

Shares at $412.62: 24.2 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $338.35

$8,200

$-1,800 (-18.0%)

12M Consensus BaseTarget $455.33

$11,035

+$1,035 (+10.4%)

12M Bull Case BreakoutTarget $537.29

$13,021

+$3,021 (+30.2%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (43 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 32● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	OUTPERFORM	$474	74%	A
Goldman SachsSector Coverage Lead	STRONG BUY	$505	69%	B
JP MorganUS Large-Cap Research	HOLD	$397	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (WST Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

WST // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +37.46%▲ ASCENDING CHANNEL

2026-11-02O $403.6H $416.7L $403.6C $412.6VOL 1.87M

RES: $440.5SUP: $348.9SMA50: $370.1SMA200: $314.9

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 WST Butterfly Map → + Track WST →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

41.2%/yr Implied 5Y Growth

vs. +6.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on WST today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

WST → LLY Confirmed Filing

West Pharmaceutical Services manufactures NovaPure fluoropolymer-coated elastomer plungers and cartridge seals required inside sterile single-dose and multi-dose GLP-1 auto-injector pens.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for WST today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WST)

Health Care Rank #14 of 1016 ⚔️ DXCM vs WST Full Matrix →

1. Head-to-Head Health Care Peer Comparison (WST vs. DXCM, RMD, MDLN, BDX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, West Pharmaceutical Services Inc. (WST) ranks #14 by composite RQD confidence (81/100, grade A-) and #59 by equity capitalization ($29.32B). Within this direct 5-issuer industry benchmark cohort, RMD leads on earnings valuation at 25.4x trailing P/E, while RMD leads on capital efficiency and profitability with 22.9% ROIC and 59.4% gross margin. RMD currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with WST at 81/100 (A-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
WST ACTIVE West Pharmaceutical Services Inc.	A-	81/100	59.4x	35.9%	17.9%	-0.97%	$29.32B	Benchmark Subject
DXCM DexCom Inc.	B+	76/100	36.1x	60.1%	21.6%	+2.95%	$30.16B	/dxcm-vs-wst →
RMD ResMed Inc.	A	86/100	25.4x	59.4%	22.9%	-9.05%	$35.56B	/rmd-vs-wst →
MDLN Medline Inc.	D	44/100	—	—	8.2%	+0.38%	$42.07B	/mdln-vs-wst →
BDX Becton Dickinson and Company	C+	67/100	32.2x	45.4%	4.9%	-0.23%	$54.03B	/bdx-vs-wst →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000105770

In its most recent audited fiscal period (FY2025, filed 2025-12-31), West Pharmaceutical Services Inc. (WST) reported GAAP revenue of $3.07B (+6.3% vs. FY2024 revenue of $2.89B , and +4.2% cumulative change since FY2023) , GAAP net income of $493.7M, operating cash flow of $754.8M, and free cash flow of $468.9M (+69.6% YoY). On the balance sheet, WST closed FY2025 with $4.27B in total assets against $202.8M in total debt (Altman Z-Score: 19.06, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.07B	$493.7M	$754.8M	$468.9M	$4.27B	$202.8M
FY2024 (FY)	2024-12-31	$2.89B	$492.7M	$653.4M	$276.4M	$3.64B	$202.6M
FY2023 (FY)	2023-12-31	$2.95B	$593.4M	$776.5M	$643.8M	$16.13B	$3.77B

3. WST Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does WST compare to DXCM and RMD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for WST?

Where is WST trading relative to its 50-day, 200-day, and 52-week technical levels?

WST last traded at $412.62 (-0.97% on volume of 1,062,356 shares), positioning the stock +11.48% above its 50-day simple moving average ($370.14) and +31.05% above its 200-day simple moving average ($314.85). Across its 52-week range of $223.83 to $438.27, WST sits at the 88.0% percentile with a 14-day RSI of 77.0 (OVERBOUGHT (>70)) and an implied next-earnings move of ±5.3% ($390.75 to $434.49).

WST Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is WST's 12-month stock price target?

West Pharmaceutical Services Inc. (WST) carries a 12-month consensus base price target of $455.33 (+10.4% from $412.62), with a bull-case target of $537.29 and a bear-case floor of $338.35.

Is WST stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates WST A- (Buy — BUY) with an RQD Confidence score of 81/100.

Direct Sub-Reports: WST RQD Cockpit WST 12M Forecast WST Earnings & Move WST Dividends & DRIP WST Insiders & 13F WST Whale Options WST Profit Sankey WST News & Why

Sector Peer Dials

Becton Dickinson and Company

Solventum Corporation

45 /100

WST Core Snapshot

Market Cap $29.32B

Trailing / Fwd P/E 59.4x / 55.2x

Gross Profit Margin 35.9%

Return on Capital (ROIC) 17.9%

Free Cash Flow Yield 1.60%

12M Base Price Target $455.33

FREE TRADER TOOLS

Own WST Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With WST → 🏆 Trade WST in $100K Prop Arena →

WST Wire

Why It Moved →

Direct Company Event Yahoo Finance • 5h ago

West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short

Peer / Ecosystem Wire TradingView • 8h ago

West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?

Peer / Ecosystem Wire Seeking Alpha • 11h ago

West Pharmaceutical: Still A Buy, But Expectations Are Rising

Direct Company Event Yahoo Finance • 14h ago

West Pharmaceutical Services (WST) Lifted Its Outlook, Is The Stock Fully Priced?

Peer / Ecosystem Wire TradingView • 17h ago

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

ROARABLE RATING BRIEF • RQD 81/100 (A-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

WST — West Pharmaceutical Services Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:12:26Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, WST scores 81 out of 100, earning a letter grade of A- and the verdict label "Roarable Buy — Superior Risk/Reward." The score is built from five pillars:

Fundamental Cash Engine (18/20): Per the RQD rating, this pillar reflects ROIC of 17.9% and an FCF yield of 1.6%. The high return on invested capital is the main strength; the low FCF yield means the market is pricing in substantial future growth relative to current free cash generation, which is a valuation tradeoff.
Whale 13F Flow (18/20): Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The source data does not itemize the underlying 13F holdings, so the magnitude of this signal cannot be independently verified here.
Insider Conviction (11/20): Per the RQD rating, this is the weakest pillar, reflecting SEC Form 4 and Congressional PTR cluster flow. The lower score suggests insider and political-disclosure activity is less one-directional than the other signals.
Macro Regime Fit (16/20): Per the RQD rating, beta is 1.08, indicating modestly above-market sensitivity to broad market moves, with sector sensitivity also factored in.
Forensic Balance Sheet (18/20): Per the RQD rating, Altman Z 19.06, Piotroski F 9/9, and Debt/Equity 0.06 indicate a very strong balance sheet with minimal leverage.

For a prospective investor, the investment case rests on high-quality returns and a clean balance sheet, offset by a demanding valuation (P/E TTM 59.4, EV/EBITDA 34.7) and weaker insider conviction. The RQD score describes the relative quality of the setup as rated; it does not establish that the stock will outperform.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
416.67	$29.32B	59.4	55.2	34.7	7.02	0.21%	1.08	$223.83 - $438.27	17.9%

Business

Per the profile, West Pharmaceutical Services Inc. is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry. Per the Butterfly Supply-Chain Graph, the company manufactures NovaPure fluoropolymer-coated elastomer plungers and cartridge seals used inside sterile GLP-1 auto-injector pens, positioning it as a component supplier to biopharma drug delivery. Not available in source data for customer concentration, segment revenue split, or detailed revenue model.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$3074.1M	$584.9M	$493.7M	N/A	$468.9M	$791.3M	$202.8M
FY 2024	$2893.2M	$569.9M	$492.7M	N/A	$276.4M	$484.6M	$202.6M
FY 2023	$2949.8M	$676.0M	$593.4M	N/A	$643.8M	N/A	$3773.9M

Per the market data, gross margin is 35.9%, operating margin 19%, and net margin 16.1%. Per the RQD rating, ROIC is 17.9%, Altman Z-Score 19.06, and Piotroski F-Score 9/9. Debt/Equity is 0.06 per the RQD rating. Reported revenue rose from $2949.8M (FY 2023) to $3074.1M (FY 2025), while FY 2023 debt of $3773.9M contrasts with $202.8M in FY 2025, a shift the source data does not explain.

Open Questions

What share of WST revenue and what share of HVP revenue is tied to GLP-1 programs, given the exposure is labeled "Undisclosed %"?
Which insider Form 4 and Congressional PTR transactions drove the Insider Conviction score of 11/20, and in which direction?
What explains the FY 2023 debt of $3773.9M relative to the $202.8M reported for FY 2025, and why is FY 2023 cash listed as N/A?
Why are EPS figures listed as N/A for all three periods while TTM EPS is 7.02?
What are the underlying 13F holders and magnitudes behind the 18/20 Whale 13F Flow pillar?

WST Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for West Pharmaceutical Services Inc. (WST) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to WST Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 5h ago

West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short

Yahoo Finance report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 8h ago

West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?

TradingView report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 11h ago

West Pharmaceutical: Still A Buy, But Expectations Are Rising

Seeking Alpha report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 14h ago

West Pharmaceutical Services (WST) Lifted Its Outlook, Is The Stock Fully Priced?

Yahoo Finance report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 17h ago

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

TradingView report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 20h ago

What to Expect From West Pharmaceutical Services' Next Quarterly Earnings Report

Yahoo Finance report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 23h ago

West Pharmaceutical Services earnings: what to look for from WST

TradingView report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

West (WST) Stock Could Be 28% Overvalued As Cash Flow Falls Short

Yahoo Finance report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

WST Bull vs. Bear Conversation Board — What's Your Call at $412.62?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON WST 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $491.67 (+18.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is WST (A- • RQD 81/100) a Buy at $416.67?

Welcome to the WST (West Pharmaceutical Services Inc.) Roar Pit. Current RQD Composite is 81/100 (Roarable Buy — Superior Risk/Reward) in Medical/Dental Instruments. Bulls point to capital efficiency (17.9% ROIC), while bears focus on valuation multiple compression (59.4x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $320.84 (-23.0%)

Spot @ $416.67

Pump the brakes on WST — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on WST, but look at what you are paying: 59.4x trailing P/E with 35.9% gross margins. Unless West Pharmaceutical Services Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $483.34 (+16.0%)

Spot @ $416.67

WST cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on WST, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $416.67 (52-wk range $223.83 - $438.27), any beat on forward guidance forces shorts and underweight funds to chase.